bioSeedin observed progress on Xaira Therapeutics regarding an AI model strat from premium data.
Published
Signal category
Research & Knowledge
Quote
“Exciting to see the progress on Xaira Therapeutics”
— Kenneth Chih-Wei Chen|bioSeedin team
Company
bioSeedin
Connecting novel therapeutics, emerging science, and technological assets to global partners and resources.
- Industry
- Financial Services
- Location
- Cambridge, US
- Company size
- 27 employees
bioSeedin is a subsidiary of ACROBiosystems Group (SHE:301080), a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. bioSeedin, one of the most preeminent asset management, public relations, and financial advisory firms for biotech and pharmaceutical companies in APAC, operates across North America, Europe, and Asia. Based on hosting the annual Biopharmaceutical Developer Innovation Conference, the largest and most influential conference in Asia, bioSeedin aggregates industrial resources across 6000 pharmaceutical enterprises worldwide. The firm provides asset management services via licensing in and out, co-developmental partner sourcing, and project implementation, as well as advising on public relation management, Asia market entry, investment strategy, mergers and acquisitions, and capital raising. bioSeedin aims to be the supreme asset transaction platform for our global clients. By facilitating R&D efficiency, maximizing research resources and funding, and emerging market access to deliver therapeutics faster and benefit our patients worldwide. If you are interested in our current assets and other services, please contact us: license@bioseedin.com; Or review our LinkedIn Posts page and check for Documents; Or visit our licensing info website https://www.bioseedin.com/licensing
Founded 2019